BioPharma Credit (LSE:BPCR) Ending Cash Position: $12.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BPCR BioPharma Credit PLC LSE:BPCR
50 GF Score
Price $0.97
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit Ending Cash Position?

BioPharma Credit LSE:BPCR +0.83% 50 Ending Cash Position is $12.6 Mil as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 50/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

BioPharma Credit's Ending Cash Position for the quarter that ended in Dec. 2025 was $12.6 Mil.

BioPharma Credit's quarterly Ending Cash Position declined from Dec. 2024 ($5.6 Mil) to Jun. 2025 ($4.3 Mil) but then increased from Jun. 2025 ($4.3 Mil) to Dec. 2025 ($12.6 Mil).

BioPharma Credit's annual Ending Cash Position declined from Dec. 2023 ($135.1 Mil) to Dec. 2024 ($5.6 Mil) but then increased from Dec. 2024 ($5.6 Mil) to Dec. 2025 ($12.6 Mil).

BioPharma Credit Ending Cash Position Related Terms

BioPharma Credit Ending Cash Position Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit Ending Cash Position Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 94.71 120.53 135.05 5.62 12.59

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.05 37.14 5.62 4.31 12.59
LSE:BPCR
50GF Score
BioPharma Credit PLC LSE:BPCR
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BioPharma Credit's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=5.62+6.967
=12.6

BioPharma Credit's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.305+8.282
=12.6

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $12.6 Mil mean?
BioPharma Credit (LSE:BPCR) has a Ending Cash Position of $12.6 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's Ending Cash Position too high?
BioPharma Credit's current Ending Cash Position is $12.6 Mil. Overall, BioPharma Credit has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Ending Cash Position compare to BLK and BX?
BioPharma Credit's Ending Cash Position of $12.6 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for an Asset Management company?
A good Ending Cash Position depends on the Asset Management industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current Ending Cash Position is $12.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.97 — trading 0.8% above its estimated fair value. The current Ending Cash Position is $12.6 Mil. BioPharma Credit's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Ending Cash Position is $12.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued. The current stock price of $0.97 is trading 0.8% above its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • Ending Cash Position: $12.6 Mil
  • GF Value™: $0.96 vs. price of $0.97 (0.8% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
50GF Score

Get the complete analysis for LSE:BPCR

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price
$0.96
GF Value